TYMS polymorphisms and responsiveness to or toxicity of methotrexate in rheumatoid arthritis; [TYMS-Polymorphismen und Empfindlichkeit gegenüber oder Toxizität von Methotrexat bei rheumatoider Arthritis]

被引：0

作者：

Bae S.-C. ^{[1
]}

Lee Y.H. ^{[2
]}

机构：

[1] Department of Rheumatology, Hospital for Rheumatic Diseases, Division of Rheumatology, Hanyang University, Hanyang

[2] Division of Rheumatology, Department of Internal Medicine, Korea University Anam Hospital, Korea University College of Medicine, 73, Inchon-ro, Seoul, 136-705, Seongbuk-gu

来源：

Zeitschrift für Rheumatologie | 2018年 / 77卷 / 9期

关键词：

Methotrexate; Rheumatoid arthritis; TYMS polymorphism;

D O I：

10.1007/s00393-018-0419-4

中图分类号：

学科分类号：

摘要：

Objective: The aim of this study was to investigate whether the thymidylate synthase (TYMS) 2R/3R and 6 bp I/D polymorphisms can predict the response to or toxicity of methotrexate (MTX) in patients with rheumatoid arthritis (RA). Methods: We conducted a meta-analysis of studies on the association between the TYMS 2R/3R and 6 bp I/D polymorphisms and non-responsiveness to or toxicity of MTX in RA patients. Results: A total of 11 studies involving 1613 patients were considered. Meta-analysis showed no association between the TYMS 2R/3R 3R allele and non-responsiveness to MTX therapy (odds ratio [OR] = 1.087, confidence interval [CI] = 0.682–1.731, p = 0.726). The meta-analysis indicated that there was no association between the TYMS 6 bp I/D D allele and non-responsiveness to MTX therapy (OR = 0.688, 95% CI = 0.281–1.683, p = 0.413). Meta-analysis revealed that the TYMS 2R/3R polymorphism was not associated with MTX toxicity, except for in a co-dominant model, and the TYMS 6 bp I/D polymorphism was not associated with MTX toxicity in all genetic models. Conclusions: This meta-analysis demonstrates that the TYMS 2R/3R and 6 bp I/D polymorphisms may not be associated with non-responsiveness to or toxicity of MTX therapy in RA patients. © 2018, Springer Medizin Verlag GmbH, ein Teil von Springer Nature.

引用

页码：824 / 832

页数：8

共 33 条

[1] Aletaha D., Smolen J.S., The rheumatoid arthritis patient in the clinic: comparing more than 1,300 consecutive DMARD courses, Rheumatology (Oxford), 41, 12, pp. 1367-1374, (2002)
[2] Banerjee D., Mayer-Kuckuk P., Capiaux G., Et al., Novel aspects of resistance to drugs targeted to dihydrofolate reductase and thymidylate synthase, Biochim Biophys Acta, 1587, 2-3, pp. 164-173, (2002)
[3] Bohanec Grabar P., Logar D., Lestan B., Et al., Genetic determinants of methotrexate toxicity in rheumatoid arthritis patients: a study of polymorphisms affecting methotrexate transport and folate metabolism, Eur J Clin Pharmacol, 64, 11, pp. 1057-1068, (2008)
[4] Borman P., Tasbas O., Karabulut H., Et al., Thymidylate synthase genetic polymorphism and plasma total homocysteine level in a group of Turkish patients with rheumatoid arthritis: relationship with disease activity and methotrexate toxicity, Rev Bras Reumatol, (2015)
[5] Chaabane S., Marzouk S., Akrout R., Et al., Genetic Determinants of Methotrexate Toxicity in Tunisian Patients with Rheumatoid Arthritis: A Study of Polymorphisms Involved in the MTX Metabolic Pathway, Eur J Drug Metab Pharmacokinet, (2015)
[6] Chen Y., Zou K., Sun J., Et al., Are gene polymorphisms related to treatment outcomes of methotrexate in patients with rheumatoid arthritis? A systematic review and meta-analysis, Pharmacogenomics, 18, 2, pp. 175-195, (2017)
[7] DerSimonian R., Laird N., Meta-analysis in clinical trials, Control Clin Trials, 7, 3, pp. 177-188, (1986)
[8] Egger M., Davey Smith G., Schneider M., Et al., Bias in meta-analysis detected by a simple, graphical test, BMJ, 315, 7109, pp. 629-634, (1997)
[9] Egger M., Smith G.D., Phillips A.N., Meta-analysis: principles and procedures, BMJ, 315, 7121, pp. 1533-1537, (1997)
[10] Felson D.T., Anderson J.J., Meenan R.F., The comparative efficacy and toxicity of second-line drugs in rheumatoid arthritis. Results of two metaanalyses, Arthritis Rheum, 33, 10, pp. 1449-1461, (1990)

← 1 2 3 4 →